调控细胞内信号通路对喉癌进行多靶点 精准治疗的设想
Precise multi-target treatment of laryngocarcinoma by regulating cell downstream signaling pathway

内皮素1/内皮素受体轴（ET 1/ETR轴）对很多恶性肿瘤的发展有调控作用。我们发现ET 1/ETR轴能显 著促进喉癌细胞增殖，但通过何种信号通路引发细胞反应尚不明确。内皮素受体属于G蛋白偶联受体，能将信号 经由G蛋白通路传递到细胞核，最终引发细胞反应；β-arrestin可以作为新的通路进行信号传导。两条通路之间不 仅存在着优势偏向，而且引发的最终生物学效果可能不一致。我们根据前期研究发现及逻辑推理，提出通过调控 ET 1/ETR轴诱发的细胞内信号通路对喉癌进行多靶点精准治疗的设想。
The endothelin 1 (ET 1)/ endothelin receptor (ETR) axis plays an important role in the pathogenesis of most malignant tumors. Our previous study has found that ET 1/ETR axis significantly promotes the proliferation of laryngeal cancer cells. However, the exact signaling pathways and downstream proteins that ultimately trigger cell responses remain elusive. ETR belongs to the G protein-coupled receptor, which can transfer the signal to the nucleus through the G protein channel and eventually induce cell response. Recent evidence reveals that β-arrestin also separately participates in signal transduction as a new signaling pathway. Ligands may preferentially activate only G protein or β-arrestinmediated downstream signaling, and confer different effects finally. Based on our previous founding and logical reasoning, we propose the assumption of precision treatment of the laryngocarcinoma by regulating the cell downstream signaling pathway activated by ET 1/ETR axis